Find Hidradenitis Suppurativa Clinical Trials Near You
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
Status: Recruiting
Location: See all (27) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 17
Healthy Volunteers: f
View:
• Aged ≥ 12 to \< 18 years at the time of informed consent/assent signing.
• Body weight ≥ 30 kg at both screening and baseline visits.
• Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
• Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
• HS lesions corresponding to refined Hurley Stage IB, IC, IIB, IIC, or III at both the screening and baseline visits.
• Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS).
• Agreement to use contraception.
• Willing and able to comply with the study protocol and procedures.
• Further inclusion criteria apply.
Locations
United States
Alabama
University of Alabama At Birmingham
NOT_YET_RECRUITING
Birmingham
Arizona
Medical Dermatology Specialists Phoenix
RECRUITING
Phoenix
Saguaro Dermatology
RECRUITING
Phoenix
Connecticut
Uconn Health
NOT_YET_RECRUITING
Farmington
Florida
Skin Research of South Florida, Llc
RECRUITING
Miami
University of Miami Miller School of Medicine
RECRUITING
Miami
Trueblue Clinical Research
RECRUITING
Tampa
Georgia
Advanced Medical Research Pc
RECRUITING
Sandy Springs
Illinois
Endeavor Health Medical Group
RECRUITING
Skokie
Kansas
Dermatology Skin Cancer Center Leawood
RECRUITING
Leawood
Kentucky
Equity Medical
RECRUITING
Bowling Green
Massachusetts
Boston Childrens Hospital
NOT_YET_RECRUITING
Boston
Maryland
Johns Hopkins Oncology Center
RECRUITING
Baltimore
Michigan
Oakland Hills Dermatology Pc
RECRUITING
Auburn Hills
Wayne State University Physician Group Dermatology
RECRUITING
Detroit
Revival Research Institute, Llc Troy
RECRUITING
Troy
Missouri
Washington University
RECRUITING
St Louis
Montana
Boeson Research Missoula 2825 Fort Missoula Rd
RECRUITING
Missoula
New Mexico
University of New Mexico Hospital
RECRUITING
Albuquerque
Pennsylvania
Geisinger Medical Center
NOT_YET_RECRUITING
Danville
Texas
Bellaire Dermatology Associates Bda
RECRUITING
Bellaire
Texas Dermatology Research Center
RECRUITING
Dallas
Utah
Jordan Valley Dermatology Center
RECRUITING
South Jordan
Other Locations
Canada
Dermcare Clinic
RECRUITING
Mississauga
York Dermatology Center
RECRUITING
Richmond Hill
Skincare Studio Dermatology Centre
NOT_YET_RECRUITING
St. John's
The Hospital For Sick Children
NOT_YET_RECRUITING
Toronto
Contact Information
Primary
Incyte Corporation Call Center (US)
medinfo@incyte.com
1.855.463.3463
Backup
Incyte Corporation Call Center (ex-US)
eumedinfo@incyte.com
+800 00027423
Time Frame
Start Date:2026-02-02
Estimated Completion Date:2028-03-25
Participants
Target number of participants:40
Treatments
Experimental: Povorcitinib Dose A
Participants will receive povorcitinib dose A for 54 weeks.
Experimental: Povorcitinib Dose B
Participants will receive povorcitinib dose B for 54 weeks.